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Summary The involvement of 5-hydroxytryptamine (5-HT) 5-HT3 receptors in the mechanisms of severe
emesis evoked by cytotoxic drugs or by total body irradiation have been studied in ferrets. Anti-emetic
compounds tested were domperidone (a dopamine antagonist), metoclopramide (a gastric motility stimulant
and dopamine antagonist at conventional doses, a 5-HT3 receptor antagonist at higher doses) and BRL 24924
(a potent gastric motility stimulant and a 5-HT3 receptor antagonist). Domperidone or metoclopramide
prevented apomorphine-evoked emesis, whereas BRL 24924 did not. Similar doses of domperidone did not
prevent emesis evoked by cis-platin or by total body irradiation, whereas metoclopramide or BRL 24924
greatly reduced or prevented these types of emesis. Metoclopramide and BRL 24924 also prevented emesis
evoked by a combination of doxorubicin and cyclophosphamide. These results are discussed in terms of a
fundamental role for 5-HT3 receptors in the mechanisms mediating severely emetogenic cancer treatment
therapies.
There have recently been two important advances relating to
the improvement of anti-emetic treatment given to patients
undergoing anti-cancer therapies. Firstly, it was found that,
unlike conventional doses of metoclopramide (Maxolon;
Beecham Pharmaceuticals) which antagonise dopamine
receptors and stimulate gastric motility, high doses of the
drug greatly reduced cis-platin-evoked emesis (Gralla et al.,
1981). In contrast, even high doses of the dopamine anta-
gonists, domperidone (Motilium; Janssen Pharmaceuticals)
or alizapride, have little or no ability to prevent cis-platin-
induced emesis (Tonato et al., 1985; Saller & Hellenbrecht,
1985). Mechanisms other than dopamine receptor
antagonism have therefore been implicated in this anti-
emetic action of metoclopramide (McRitchie et al., 1984).
Secondly, metoclopramide is an antagonist of 5-hydroxy-
tryptamine (5-HT) acting on 5-HT3 receptors (previously
known as 5-HT M-receptors; see Bradley et al., 1986 for
definition of this receptor) located in the peripheral nervous
system (Fozard, 1984a); the effective concentrations of meto-
clopramide are higher than those required to antagonise
dopamine receptors or to stimulate gut motility (Sanger,
1984). We subsequently suggested that such high doses of
metoclopramide may prevent cis-platin-induced emesis by
means of antagonising 5-HT3 receptors (Miner & Sanger,
1986).
The involvement of 5-HT3 receptors in the mechanisms of
emesis have now been further investigated using chemo- and
radio-emetic stimuli in the ferret. The ferret has previously
been shown to be suitable for studying emesis evoked by cis-
platin (Florczyk et al., 1982; Miner & Sanger, 1986), a
combination of doxorubicin and cyclophosphamide (Schurig
et al., 1984) or by whole-body irradiation (Andrews et al.,
1986; Gylys & Gidda, 1986).
The drugs tested were domperidone, metoclopramide and
BRL 24924, a novel benzamide. BRL 24924 is a potent and
highly effective stimulant of gastric motility, which in
contrast to metoclopramide or domperidone, lacks the ability
to antagonise dopamine receptors (Cooper et al., 1986).
Accordingly, the compound has recently entered clinical
trials as a new, potent gastric prokinetic agent, without the
potential to cause side-effects that may be related to
dopamine antagonism within the central nervous system. In
addition, BRL 24924 is an antagonist of 5-HT3 receptors
(Sanger, 1987) and can therefore be used in animals to
investigate the involvement of 5-HT3 receptors in the
mechanisms of emesis. Preliminary results with BRL 24924
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and cis-platin have previously been presented to the British
Pharmacological Society (Miner et al., 1986).
Materials and methods
Surgery
Male ferrets (1.0-1.9 kg) were used. A chronic, indwelling
venous catheter was implanted using a modification of the
technique described by Florczyk and Schurig, 1981. Prior to
surgery, each ferret was sedated with ketamine hydrochloride
(Vetalar, Parke-Davis; 40mg/animal, i.m.) and anaesthetised
with a halothane-N20:02 mixture. A 4 day recovery period
was allowed before further procedures. At the end of each
experiment, catheter patency was confirmed by injection of a
lethal dose of sodium pentobarbitol (Euthatal; May and
Baker).
Emesis evoked by apomorphine
Subcutaneous injection of apomorphine 200jgkg 1 was
used to evoke emesis. The time at which each vomit
occurred was noted, as was the time interval from injection
of apomorphine to the first vomit (latency period). An
emetic episode was defined as commencing when a ferret
assumed a characteristic posture with retching and was
concluded when either vomitus was expelled or was present
in the mouth as demonstrated by chewing. Metoclopramide,
domperidone and BRL 24924 were each injected i.v. 15min
before apomorphine.
Emesis evoked by cis-platin
Ferrets were obtained from two different suppliers and
exhibited small differences in sensitivity to cis-platin. For
each group of animals, an i.v. dose of cis-platin was
therefore pre-determined as being the minimum dose
required to evoke a consistent emetic response (respectively,
7.1 or 10mgkg-1 cis-platin). In contrast to apomorphine,
the emesis evoked by cis-platin was relatively long-lasting
and occurred after a long latency (see Results). Potential
anti-emetic compounds were therefore injected i.v. 30min
before and then again, 45min after cis-platin. This type of
dosing regime was previously described by Florczyk et al.
(1982), as an effective means of reducing cis-platin-induced
emesis in ferrets by metoclopramide. Ferrets were observed
for 240min after injection of cis-platin and emesis was
quantified as described for the studies with apomorphine.
For those ferrets which did not vomit, the latency period
was taken as 240min.
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Emesis evoked by doxorubicin and cyclophosphamide
Preliminary studies indicated that a consistent emetic
response was obtained using a combination of doxorubicin
6 mgkg- i.v., quickly followed by cyclophosphamide
80mgkg- I i.v. Compared with cis-platin, the latency period
was shorter and to allow for this, potential anti-emetic
compounds were injected i.v. 30 min before and 30min after
doxorubicin and cyclophosphamide. Emesis was quantified
as described for apomorphine and cis-platin.
Emesis evoked by X-irradiation
Ferrets were contained within a ventilated perspex box and
the whole body was exposed to X-rays. The X-ray source
(Machlett, Model OEG-50, Tungsten anode) was - 25 cm
from the upper surface of the ferret and was operated at
50kV and 20mA through a mm berylium window and a
0.18 mm aluminium filtration. This low irradiation energy
produced a low penetration X-ray beam at an estimated
3 Gymin-. Following 10.4min irradiation, ferrets were
returned to their pens and observed for 120min. The latency
period was defined as the time from the start of irradiation
to the first vomit. In ferrets completely protected from
vomiting, the latency period was taken as 120min.
Compared with cytotoxic drug-induced emesis, the vomiting
caused by the radiation was of shorter duration. Potential
anti-emetic compounds were therefore injected i.v. 1-4min
before the start of irradiation.
Drugs
The following cytotoxic drugs were diluted in water for
injection BP: cis-platin (Neoplatin for injection; Bristol-
Myers), doxorubicin (Adriamycin for injection; Farmitalia)
and cyclophosphamide (Endoxana for injection; W.B.
Pharmaceuticals). Apomorphine hydrochloride was dissolved
in 0.05% w/v sodium metabisulphite solution. Doses of BRL
24924 ((±)-(endo)-4-amino- 5-chloro -2methoxy -N-(l-
azabicyclo [3.3.l]non-4-yl) benzamide hydrochloride;
Beecham Pharmaceuticals), metoclopramide (Beecham
Pharmaceuticals) and domperidone (synthesised in-house)
were calculated as free base and dissolved in water for
injection BP.
Statistical analysis
Results are expressed as means + s.e.m. and were analysed
using the Mann-Whitney U-test.
Results
Emesis evoked by apomorphine
Metoclopramide 1.25mgkg- 1 i.v. or domperidone
1.0mgkg-1 i.v. prevented emesis in all ferrets tested. BRL
24924 1.25mgkg- 1 i.v. had no effects on apomorphine-
evoked emesis (Table I).
Emesis evoked by cis-platin
Cis-platin-evoked emesis began approximately 80min after
injection and usually consisted of 4 to 6 groups of vomiting
episodes with 3 to 4 individual vomits per group. Vomiting-
free periods (10 to 30min) separated the groups of vomiting
episodes. Compared with the control ferrets, BRL 24924
2 x 0.65, 2 x 1.25 and 2 x 2.5 mgkg- I i.v. reduced the mean
number of vomits by respectively 62%, 83% and 83%; the
latency period was correspondingly increased (Table II).
Metoclopramide 2 x 0.65, 2 x 1.25 and 2 x 2.5mgkg- 1 i.v.
similarly reduced the emesis evoked by cis-platin, whereas
domperidone 2 x 1.0 and 2 x 2.5mgkg-1 i.v. had no effects
(Table II).
Table I Apomorphine-evoked vomiting
Latency Number
Number of period of
Treatment ferrets tofirst emetic
(mgkg1 i.v.) vomiting/tested vomit (min) episodes
Control - 6/6 2.7+0.5 5.0+0.7
BRL 24924 1.25 3/3 2.3+0.3 9.0+1.5
Metoclopramide 1.25 0/3 30.0+0.oa 0.0+0.0a
Domperidone 1.0 0/3 30.0+O.oa 0.0 +O.Oa
All ferrets given apomorphine 200,pgkg-1 s.c., 15 min after an
anti-emetic; ap<0.05 compared with control ferrets. If a ferret did
not vomit, latency period was taken as equal to the observation
period (30min). Results are given as mean+s.e.
Table II Cis-platin-evoked vomiting
Latency Number
Number of period of
Treatment ferrets tofirst emetic
(mgkg- i.v.) vomiting/tested vomit (min) episodes
Control (a) 19/20 81.3+8.9 16.5+1.5
Control (b) - 10/10 84.7+5.4 18.4+2.4
BRL 24924 (a) 2x0.65 5/6 138.5+21.2b 6.2+2.5a
BRL 24924 (a) 2 x 1.25 2/6 196.5+27.6b 2.8+2.lb
BRL 24924 (a) 2 x 2.5 3/6 168.5 +32.7a 2.8 + 1.5b
Metoclopramide (b) 2 x 0.65 5/6 139.0+22.7a 4.7+ 2.2a
Metoclopramide (b) 2 x 1.25 4/6 160.7+26.4a 4.2+2.la
Metoclopramide (b) 2 x 2.5 1/6 217.5 +22.5b 1.8+ 1.8b
Domperidone (b) 2 x 1.0 5/5 57.6+ 13.6 18.4+5.3
Domperidone (a) 2 x 2.5 4/4 62.5 +6.7 15.5 +2.2
All ferrets given cis-platin (a) 10.0, or (b) 7.1mgkg-1 i.v. Anti-
emetic compounds were given 30min before and then again, 45min
after cis-platin. Compared with controls, ap<0.05, bp<0.01. If a
ferret did not vomit, latency period was taken as equal to the
observation period (240min). Results are given as mean+ s.e.
Table III Doxorubicin/cyclophosphamide-evoked vomiting
Latency Number
Number of period of
Treatment ferrets to first emetic
(mgkg1 i.v.) vomiting/tested vomit (min) episodes
Control - 8/8 39.6+5.9 35.6+3.1
BRL 24924 2x0.65 2/4 218.0+18.5b 2.5+1.7b
BRL 24924 2 x 1.25 0/4 240.0+O.Ob 0.0+ O.Ob
Metoclopramide 2 x 2.5 4/4 114.3 +2.2b 10.5+3.4b
All ferrets given doxorubicin 6mgkg-1 i.v. and cylophosphamide
80mgkg-1 i.v. Anti-emetic compounds were given 30min before and
then again, 30min after doxorubicin. Compared with controls,
ap<0.05, bP<0.01. If a ferret did not vomit, latency period was
taken as equal to the observation period (240nm). Results are given
as mean +s.e.
Emesis evoked by doxorubicin and cyclophosphamide
The pattern of emesis evoked by doxorubicin 6mgkg-1 i.v.
and cyclophosphamide 80mgkg- i.v. was similar to that
evoked by cis-platin, except that the latency period was
shorter (Tables II & III). Compared with the control ferrets,
BRL 24924 2 x 0.65 and 2 x 1.25mgkg-1 i.v. reduced the
mean number of vomits by respectively 90% and 100%.
Metoclopramide 2 x 2.5mgkg-1 i.v. reduced the mean
number of vomits by 59% (Table III).EMESIS AND 5-HYDROXYTRYPTAMINE3 RECEPTORS 161
Table IV Radiation-evoked vomiting
Latency Number
Number of period of
Treatment ferrets tofirst emetic
(mgkg i.v.) vomiting/tested vomit (min) episodes
Control - 5/5 19.4±1.1 28.8+1.3
BRL 24924 0.25 3/4 64.0+ 18.7a 7.8+3.3a
BRL 24924 1.25 3/5 79.2+ 16.7b 1.2+0.6b
Domperidone 1.25 4/4 21.8 + 1.9 25.5 + 1.3
Domperidone 2.5 4/4 25.8+4.0 195.+ 5.1
All ferrets X-irradiated for 10.4min. Anti-emetic compounds were
given 1-4min before the start of irradiation. Compared with
controls, ap<0.05, bp<0.01. If a ferret did not vomit, latency
period was taken as equal to the observation period (120min).
Results are given as mean +s.e.
Emesis evoked by X-irradiation
The pattern of emesis evoked by total body X-irradiation
was highly consistent, beginning 19.4+ 1.1 min after the start
of irradiation (Table IV). Most of the emesis (70% of the
total) occurred during the first 40min after the start of
irradiation and in the present experiments, vomiting was
never observed 101 min from the start of irradiation, at
which time the animals appeared normal. BRL 24924 0.25
and 1.25 mgkg- 1 i.v. reduced the mean number of vomits by
respectively 73% and 96%. Domperidone 1.25 and
2.5mgkg- 1 i.v. did not significantly reduce the emesis,
although the higher dose of domperidone did tend to reduce
the number of vomits (Table IV).
Discussion
Our experiments with ferrets and domperidone confirm the
inability of dopamine antagonists to inhibit emesis evoked
by cis-platin, even though a similar dose of domperidone
prevented apomorphine-evoked emesis. Similarly, haloperidol
and sulpiride do not prevent cis-platin-evoked emesis in dogs
(Gylys et al., 1979; Alphin et al., 1986). Dopamine receptors
therefore do not play an important part in the mechanism
by which strongly emetogenic cytotoxic drugs evoke
vomiting in animals, supporting the results obtained in
cancer patients. However, our experiments do not rule out
the possibility that dopamine receptors may be involved in
the mechanism of emesis evoked by less severe emetogenic
cytotoxic drugs.
It has been suggested that the increase in gastrointestinal
motility caused by metoclopramide can inhibit cis-platin-
evoked emesis (Alphin et al., 1986). However, the inability of
conventional doses of metoclopramide or of domperidone to
inhibit cis-platin-evoked emesis is in marked conflict with
this suggestion. At these doses, both drugs have been shown
to stimulate gut motility in man and a variety of small
laboratory animals (Brogden et al., 1982; Harrington et al.,
1983). The gastric prokinetic activity of metoclopramide and
BRL 24924 may, nevertheless, prevent nausea and vomiting
associated with other conditions. These include delayed gastric
emptying, tachygastria and gastrointestinal dysrhythmia
(You et al., 1981; Cottrell et al., 1982; Geldof et al., 1986).
The unlikely involvement of dopamine antagonism or of
gut stimulation in the mechanisms by which high doses of
metoclopramide reduced cis-platin-evoked emesis, led to the
proposal that 5-HT3 receptor antagonism is important in the
anti-emetic actions of metoclopramide (Miner & Sanger,
1986). Thus, the anti-emetic activity of metoclopramide
could be mimicked in ferrets by MDL 72222, an
experimental selective 5-HT3 receptor antagonist, which does
not block dopamine receptors or increase gut motility
(Fozard, 1984b). A subsequent study, using a different 5-
HT3 receptor antagonist supports the involvement of 5-HT
in emesis (Costall et al., 1986), but in these experiments, the
post-surgical trauma, the anaesthetic used and the severe
stress experienced by the ferrets may also contribute to the
emesis observed after cis-platin injection. The present
experiments in ferrets with doses of BRL 24924 which did
not block apomorphine-evoked emesis, now add further
weight to the proposal that 5-HT3 receptor antagonism can
reduce or prevent cis-platin-evoked emesis. In addition, the
severe emesis induced in ferrets by doxorubicin and cyclo-
phosphamide, or the emesis induced by whole body
irradiation were also prevented by BRL 24924.
Dubois et al. (1984) and Gylys and Gidda (1986) found
that domperidone prevented radiation-evoked emesis in dogs
and ferrets; Dorval et al. (1985) found no effects of
domperidone on radiation-evoked emesis in monkeys. Our
results with ferrets suggest that a high dose of domperidone
may slightly reduce the severity of radiation-evoked emesis,
but this apparent reduction was not statistically significant.
Different intensities of X-irradiation may account for the
different results between experimentors (Young, 1986).
However, if dopamine receptors do have a role in the
mechanism by which radiation can evoke emesis, the
prevention of radiation-evoked emesis by BRL 24924
suggests that their involvement may be dominated by a more
essential role of 5-HT3 receptors.
In conclusion, our results suggest that in ferrets, different
emetic stimuli evoke emesis by acting at a common point
involving 5-HT3 receptors. It seems likely that these results
will also apply to man, since the anti-emetic potential of
metoclopramide and the inactivity of domperidone closely
mimics that found in cancer patients. Furthermore, because
high doses of metoclopramide reduce cis-platin-evoked
emesis by antagonising 5-HT3 receptors (Miner & Sanger,
1986), it necessarily follows that more selective 5-HT3
receptor antagonists should be effective anti-emetic drugs in
cancer patients.
Emesis evoked in ferrets by cyclophosphamide or by X-
irradiation is greatly reduced by abdominal vagotomy and
sympathectomy (Andrews et al., 1986; 1987), but it is not yet
known to what extent the 5-HT3 receptors are located in the
peripheral nervous system or at a central nerve site, such as
the area postrema (Miner & Sanger, 1986). During X-
irradiation, large amounts of 5-HT can be liberated from the
enterochromaffin cells of the intestine (Matsouka et al.,
1962), whereas there has been no previous, satisfactory
association of 5-HT with the actions of cytotoxic drugs.
Perhaps the inhibition by cytotoxic drugs of the enzymes
which break down neurotransmitters (Harris, 1982) leads to
a rise in the amounts of 5-HT present in the gut and/or area
postrema. It is possible that this action may depend on the
anti-cancer regime employed, so that varying rates of 5-HT
release or synthesis, may explain the different latency periods
obtained with different cytotoxic drugs. Wherever the site of
action, an increased awareness that 5-HT3 receptors are
fundamentally important in the mechanisms of emesis now
make it possible to specifically design drugs with increased
potency, selectivity and efficacy, to prevent the distressing
and debilitating nausea and vomiting which can accompany
different types of treatment for cancer. In this respect, we
have already shown that BRL 43694, a novel compound
with an improved selectivity and potency as a 5-HT3
receptor antagonist, provides an even more effective control
of cytotoxic drug or radiation-evoked emesis in ferrets
(Boyle et al., 1987).
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